Showing 4651-4660 of 6946 results for "".
- New AD Research Indicates 'New Standards of Care'https://practicaldermatology.com/news/new-ad-research-indicates-new-standards-care/2468544/The bar has been raised for atopic dermatitis (AD). That was the message in “Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis,” a presentation from Drs. Christopher Bunick, Brad Glick, and Alexandra Gol
- FDA Approves Emrosi for Rosaceahttps://practicaldermatology.com/news/fda-approves-emrosi-rosacea-treatment/2468543/The US Food and Drug Administration (FDA) has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) as a treatment for inflammatory lesions of rosacea in adults. According to a press release from the manufacturer, Journey Medical (in partnership with Dr.
- Patrick J. Byrne Named President of AAFPRS for 2024-2025https://practicaldermatology.com/news/patrick-j-byrne-named-president-aafprs-2024-2025/2468542/Dr. Patrick J. Byrne, MD, MBA, has been installed as the 2024-2025 President of the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). Dr. Byrne, the Enterprise Chief of the Cleveland Clinic Integrated Surgical Institute and Chair of the Head and Neck Surgery Departmen
- Vichy Dercos Launches Advanced Scalp Line in US Markethttps://practicaldermatology.com/news/vichy-dercos-launches-advanced-scalp-solutions-us-market/2468512/Vichy Decros has announced the US launch of its new three-step system targeting scalp concerns, representing w
- Starton Secures New Patent for Transdermal Lenalidomide Deliveryhttps://practicaldermatology.com/news/starton-secures-new-patent-transdermal-lenalidomide-delivery/2468506/Starton Therapeutics announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its STAR-LLD transdermal drug delivery patent application, providing potential extended patent protection through 2040. According to a press release, the development broad
- ImmunoSkin Conference Explores Inflammatory Skin Conditionshttps://practicaldermatology.com/news/immunoskin-conference-explores-inflammatory-skin-conditions/2468494/The third annual ImmunoSkin conference was held October 26-27 in Barcelona, Spain, highlighting new therapeutic strategies and facilitating exchange about the biological mechanisms of psoriasis and atopic dermatitis through clinical case studies and expert debates. The event was hosted by
- Positive Results for Guselkumab for Moderate PsO Patientshttps://practicaldermatology.com/news/positive-results-guselkumab-moderate-pso-patients/2468490/Guselkumab treatment resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, according to data presented at the 44th Annual Fall Clinical Dermatology Conferenc
- Details Revealed for Upcoming Phase 2 Study for New AD Drug from Apogeehttps://practicaldermatology.com/news/details-revealed-upcoming-phase-2-study-new-ad-drug-apogee/2468489/Apogee Therapeutics’ half-life-extended monoclonal antibody APG777 for atopic dermatitis was the subject of a poster presented by Dr. Emma Guttman-Yassky and others at the 44th Annual Fall Clinical Dermatology Conference. The poster detailed the design of the phase 2 APEX study. “IL
- Promising Pipeline for CSU Optionshttps://practicaldermatology.com/news/promising-pipeline-csu-options/2468488/Cleveland Clinic allergist Dr. David Lang joined Dr. Dawn Merritt and Dr. Brad P. Glick to discuss chronic spontaneous urticaria (CSU) at the 44th Annual Fall Clinical Dermatology Conference and noted that the future is very promising. “Our recent understanding of chronic urticaria has imp
- Lecture Updates on Abrocitinib, Povorcitinib for PNhttps://practicaldermatology.com/news/lecture-updates-abrocitinib-povorcitinib-pn/2468486/Dr. Shawn Kwatra gets goosebumps when he thinks about having two approved biologics for prurigo nodularis, (PN) he said during a session at the 44th Annual Fall Clinical Dermatology Conference. “I have to pinch myself,” Dr. Kwatra said during “Making the Connection Between Prurigo Nodulari